Brief: Cerevel Therapeutics Reports Second Quarter 2022 Financial Results

Cerevel Therapeutics Holdings

01/08/2022 12:59

Aug 1 (Reuters) - Cerevel Therapeutics Holdings Inc
 CERE.O :
    * CEREVEL THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS AND BUSINESS UPDATES
    * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $531M
AS OF
JUNE 30, 2022, TO SUPPORT OPERATIONS INTO 2024
    * CEREVEL THERAPEUTICS HOLDINGS - INITIATED TWO PARALLEL,
ADEQUATELY-POWERED PHASE 2 TRIALS OF EMRACLIDINE IN
SCHIZOPHRENIA WITH DATA EXPECTED 1H 2024
    * CEREVEL THERAPEUTICS - PHASE 1 TRIAL OF EMRACLIDINE TO BE
INITIATED BY YEAR-END TO SUPPORT FUTURE DEVELOPMENT IN
ALZHEIMER'S DISEASE PSYCHOSIS
    * QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.61
    * Q2 EARNINGS PER SHARE VIEW $-0.48 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX65FkBw 
Further company coverage:  CERE.O 

 ((Reuters.Briefs@thomsonreuters.com;))